Fairvalue-Calculator Fairvalue-Calculator
EN DE

curacle co.,ltd., a bio-venture business, (365270) Fair Value & Analysis

Healthcare · KR · Market cap 258B KRW

Price12,250 KRW
Fair Value7,664 KRW
Upside-37.4%
Quality95/100
Evidence: Low Range 5,748 KRW – 9,580 KRW

Fair value as of: Jun 24, 2026

✦ Find undervalued quality stocks — 34,000+ analysed Find stocks →

Analysis

curacle co.,ltd., a bio-venture business, (365270) currently trades at 12,250 KRW, while our model-based Fair Value estimate is 7,664 KRW — implying the stock looks roughly 37.4% overvalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).

About the company

curacle co.,ltd., a bio-venture business, engages in the research and development of drugs for intractable vascular and metabolic diseases due to aging. The company's products in pipeline include CU06, a next-generation oral therapy, which completed phase 2a clinical trial for the treatment of diabetic macular edema; CU01, which completed Phase 2b clinical trial for Nrf2 activation and inhibition of TGF- ß/Smad signaling; MT-101, a fully humanized Tie2 agonist antibody for the treatment of renal diseases; and MT-103, a bispecific antibody combining Tie2 agonist and anti-VEGF functions for the treatment of wAMD. It also develops MT-105 for the treatment of irritable bowel diseases; MT-201, a non-bleeding anti-thrombotic antibody targeting PD-X; MT-202, a dual-mechanism therapy combining PD-X inhibition and Tie2 agonism for the treatment of acute ischemic stroke and heart failure with preserved ejection fraction; CU71, a next-generation neurovascular stabilizer for the treatment of al…

Open the full interactive analysis →

Similar stocks

Vertex Pharmaceuticals Incorporated (VRTX34) -38% Regeneron Pharmaceuticals, Inc (REGN) -14% UCB SA (UCB) -27% argenx SE (ARGNF) -57% Samsung Biologics Co (207940) -28% Alnylam Pharmaceuticals, Inc (ALNY) -63%

Frequently asked questions

Is curacle co.,ltd., a bio-venture business, (365270) undervalued?
As of Jun 24, 2026, our model estimates a fair value of 7,664 KRW versus a price of 12,250 KRW — about −37% (overvalued). Model-based estimate, not financial advice.
What is the fair value of 365270?
Our 21-model fair value for curacle co.,ltd., a bio-venture business, is 7,664 KRW (as of Jun 24, 2026), built from audited fundamentals. The current price is 12,250 KRW.
What is the quality score of 365270?
curacle co.,ltd., a bio-venture business, has a Quality Score of 95/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.